Black Rock Inc. Vigil Neuroscience, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 405,043 shares of VIGL stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

405,043

Previous 877,032 53.82%

Holding current value

$3.26 Million

Previous $2.99 Million 45.82%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.51 - $4.66 $1.18 Million - $2.2 Million	-471,989 Reduced 53.82%	405,043 $1.62 Million
Q1 2024 May 10, 2024	SELL	$2.68 - $3.63 $112,828 - $152,823	-42,100 Reduced 4.58%	877,032 $2.99 Million
Q4 2023 Feb 13, 2024	BUY	$2.97 - $8.6 $213,403 - $617,935	71,853 Added 8.48%	919,132 $3.11 Million
Q3 2023 Nov 13, 2023	BUY	$4.8 - $9.92 $123,969 - $256,203	25,827 Added 3.14%	847,279 $4.57 Million
Q2 2023 Aug 11, 2023	BUY	$8.11 - $10.54 $5.83 Million - $7.58 Million	719,366 Added 704.67%	821,452 $7.72 Million

Q1 2023 May 12, 2023	SELL	$8.77 - $12.7 $2,674 - $3,873	-305 Reduced 0.3%	102,086 $999,000
Q4 2022 Feb 13, 2023	BUY	$8.74 - $15.99 $5,820 - $10,649	666 Added 0.65%	102,391 $1.28 Million
Q3 2022 Nov 14, 2022	SELL	$2.37 - $9.61 $5,920 - $24,005	-2,498 Reduced 2.4%	101,725 $926,000
Q2 2022 Aug 12, 2022	SELL	$2.23 - $7.81 $444,809 - $1.56 Million	-199,466 Reduced 65.68%	104,223 $269,000
Q1 2022 May 12, 2022	BUY	$7.03 - $17.29 $2.13 Million - $5.25 Million	303,689 New	303,689 $2.14 Million

Others Institutions Holding VIGL

# of Institutions

Shares Held

4.69M

Call Options Held

Put Options Held

View Full List

About Vigil Neuroscience, Inc.

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $228M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

More about VIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account